Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1925 1
1959 1
1964 1
1965 2
1966 1
1969 1
1971 2
1972 1
1973 3
1974 1
1975 16
1976 8
1977 4
1978 12
1979 10
1980 14
1981 18
1982 19
1983 22
1984 27
1985 28
1986 25
1987 29
1988 32
1989 48
1990 40
1991 44
1992 44
1993 49
1994 58
1995 61
1996 72
1997 84
1998 87
1999 103
2000 101
2001 82
2002 80
2003 96
2004 123
2005 137
2006 113
2007 129
2008 145
2009 172
2010 161
2011 190
2012 180
2013 215
2014 234
2015 217
2016 184
2017 175
2018 209
2019 217
2020 217
2021 275
2022 208
2023 184
2024 151
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,635 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.
Ghia P, Pluta A, Wach M, Lysak D, Šimkovič M, Kriachok I, Illés Á, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery EJ, Lee JH, Usenko G, Wang MH, Yu T, Jurczak W. Ghia P, et al. Hemasphere. 2022 Nov 14;6(12):e801. doi: 10.1097/HS9.0000000000000801. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36398134 Free PMC article.
ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator's choice of idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in patients with relapsed/refractory (R/R) CLL. ...Patients with R/R CLL received oral acalabrutinib 100 mg twice daily …
ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator's choice of idelalisib plus rituximab (IdR) or bendamustine …
Transcriptomics technologies.
Lowe R, Shirley N, Bleackley M, Dolan S, Shafee T. Lowe R, et al. PLoS Comput Biol. 2017 May 18;13(5):e1005457. doi: 10.1371/journal.pcbi.1005457. eCollection 2017 May. PLoS Comput Biol. 2017. PMID: 28545146 Free PMC article.
Transcriptomics technologies are the techniques used to study an organism's transcriptome, the sum of all of its RNA transcripts. The information content of an organism is recorded in the DNA of its genome and expressed through transcription. ...There are two key contempor …
Transcriptomics technologies are the techniques used to study an organism's transcriptome, the sum of all of its RNA transcripts. The …
A Pseudomonas aeruginosa small RNA regulates chronic and acute infection.
Cao P, Fleming D, Moustafa DA, Dolan SK, Szymanik KH, Redman WK, Ramos A, Diggle FL, Sullivan CS, Goldberg JB, Rumbaugh KP, Whiteley M. Cao P, et al. Nature. 2023 Jun;618(7964):358-364. doi: 10.1038/s41586-023-06111-7. Epub 2023 May 24. Nature. 2023. PMID: 37225987 Free PMC article.
Toward Understanding Death.
Dolan SB, Mahon BE, Dowell SF, Zaidi A. Dolan SB, et al. Clin Infect Dis. 2021 Dec 15;73(Suppl_5):S341-S342. doi: 10.1093/cid/ciab809. Clin Infect Dis. 2021. PMID: 34910167 Free PMC article.
An interview with Liam Dolan.
[No authors listed] [No authors listed] Development. 2024 Oct 15;151(20):dev204440. doi: 10.1242/dev.204440. Epub 2024 Oct 28. Development. 2024. PMID: 39465624
Liam Dolan is a Group Leader at the Gregor Mendel Institute of Molecular Plant Biology (GMI) in Vienna, Austria, interested in intersection of plant development, evolution and ecology using the emerging model system Marchantia polymorpha. We met with Liam at the GMI to lea …
Liam Dolan is a Group Leader at the Gregor Mendel Institute of Molecular Plant Biology (GMI) in Vienna, Austria, interested in inters …
Women's health update: A literature review impacting primary care.
Dolan BM, Merriam S, Prifti CA, Walsh JM. Dolan BM, et al. Cleve Clin J Med. 2022 Jul 1;89(7):373-381. doi: 10.3949/ccjm.89a.21123. Cleve Clin J Med. 2022. PMID: 35777837 Free article. Review.
The authors review studies on key issues in women's health with potential impact on internal medicine practice. The reviewed articles discuss cardiovascular disease risks, bone health, breast cancer genetics, cervical cancer prevention, depression in the peripartum period, …
The authors review studies on key issues in women's health with potential impact on internal medicine practice. The reviewed articles …
It's Not All About Breast Density: Risk Matters.
Dolan NC, Goel MS. Dolan NC, et al. Ann Intern Med. 2015 May 19;162(10):729-30. doi: 10.7326/M15-0821. Ann Intern Med. 2015. PMID: 25984851 No abstract available.
Jacob Whitman Bailey (1811-1857): Ehrenberg's ambassador to America.
Dolan JR. Dolan JR. Eur J Protistol. 2022 Aug;85:125907. doi: 10.1016/j.ejop.2022.125907. Epub 2022 Jul 2. Eur J Protistol. 2022. PMID: 35863092 Review.
His name maybe familiar to specialists who focus on diatoms, foraminifera, or radiolaria. However, Bailey's important contributions to protistology have received very little attention and he is rarely mentioned in histories of protistology. Here Jacob Bailey's life, …
His name maybe familiar to specialists who focus on diatoms, foraminifera, or radiolaria. However, Bailey's important contributions t …
Effective presentation skills.
Dolan R. Dolan R. FEMS Microbiol Lett. 2017 Dec 29;364(24). doi: 10.1093/femsle/fnx235. FEMS Microbiol Lett. 2017. PMID: 29106534
Most PhD's will have a presentation component during the interview process, as well as presenting their work at conferences. ...
Most PhD's will have a presentation component during the interview process, as well as presenting their work at conferences. ...
4,635 results